MedicaidPrior AuthMedium impact
Darzalex Faspro™ (daratumumab and hyaluronidase- fihj) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Jun 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Darzalex Faspro (daratumumab and hyaluronidase-fihj) subcutaneous solution effective June 1, 2026, for Indiana Medicaid patients. Coverage requires meeting specific diagnosis and combination therapy criteria for multiple myeloma, light chain amyloidosis, or smoldering multiple myeloma.
Action Required
Before June 1, 2026: Billing team must implement prior authorization requirements for Darzalex Faspro subcutaneous solution for Indiana Medicaid patients. Update system to require documentation of qualifying diagnosis (multiple myeloma, light chain amyloidosis, or smoldering multiple myeloma) and appropriate combination therapy protocols. Train staff on new approval criteria and exclusions including disease progression while taking daratumumab.